156 related articles for article (PubMed ID: 23319060)
1. DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial.
Yonemitsu Y; Matsumoto T; Itoh H; Okazaki J; Uchiyama M; Yoshida K; Onimaru M; Onohara T; Inoguchi H; Kyuragi R; Shimokawa M; Ban H; Tanaka M; Inoue M; Shu T; Hasegawa M; Nakanishi Y; Maehara Y
Mol Ther; 2013 Mar; 21(3):707-14. PubMed ID: 23319060
[TBL] [Abstract][Full Text] [Related]
2. Improved quality of life in patients with no-option critical limb ischemia undergoing gene therapy with DVC1-0101.
Matsumoto T; Tanaka M; Yoshiya K; Yoshiga R; Matsubara Y; Horiuchi-Yoshida K; Yonemitsu Y; Maehara Y
Sci Rep; 2016 Jul; 6():30035. PubMed ID: 27418463
[TBL] [Abstract][Full Text] [Related]
3. Clinical Safety and Preliminary Efficacy of Plasmid pUDK-HGF Expressing Human Hepatocyte Growth Factor (HGF) in Patients with Critical Limb Ischemia.
Cui S; Guo L; Li X; Gu Y; Fu J; Dong L; Song H; Chen X; Lu Y; Hu C; Xiao F; Zhu D; Wu Z; Zhang Q
Eur J Vasc Endovasc Surg; 2015 Oct; 50(4):494-501. PubMed ID: 26122834
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease.
Makino H; Aoki M; Hashiya N; Yamasaki K; Azuma J; Sawa Y; Kaneda Y; Ogihara T; Morishita R
Arterioscler Thromb Vasc Biol; 2012 Oct; 32(10):2503-9. PubMed ID: 22904270
[TBL] [Abstract][Full Text] [Related]
5. Newly-developed Sendai virus vector for retinal gene transfer: reduction of innate immune response via deletion of all envelope-related genes.
Murakami Y; Ikeda Y; Yonemitsu Y; Tanaka S; Kondo H; Okano S; Kohno R; Miyazaki M; Inoue M; Hasegawa M; Ishibashi T; Sueishi K
J Gene Med; 2008 Feb; 10(2):165-76. PubMed ID: 18074401
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety of intramuscular gene transfer of non-viral FGF1 for peripheral artery disease.
Niebuhr A; Henry T; Goldman J; Baumgartner I; van Belle E; Gerss J; Hirsch AT; Nikol S
Gene Ther; 2012 Mar; 19(3):264-70. PubMed ID: 21716303
[TBL] [Abstract][Full Text] [Related]
7. Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2.
Masaki I; Yonemitsu Y; Yamashita A; Sata S; Tanii M; Komori K; Nakagawa K; Hou X; Nagai Y; Hasegawa M; Sugimachi K; Sueishi K
Circ Res; 2002 May; 90(9):966-73. PubMed ID: 12016262
[TBL] [Abstract][Full Text] [Related]
8. SDF-1 plasmid treatment for patients with peripheral artery disease (STOP-PAD): Randomized, double-blind, placebo-controlled clinical trial.
Shishehbor MH; Rundback J; Bunte M; Hammad TA; Miller L; Patel PD; Sadanandan S; Fitzgerald M; Pastore J; Kashyap V; Henry TD
Vasc Med; 2019 Jun; 24(3):200-207. PubMed ID: 30786835
[TBL] [Abstract][Full Text] [Related]
9. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial.
Comerota AJ; Throm RC; Miller KA; Henry T; Chronos N; Laird J; Sequeira R; Kent CK; Bacchetta M; Goldman C; Salenius JP; Schmieder FA; Pilsudski R
J Vasc Surg; 2002 May; 35(5):930-6. PubMed ID: 12021709
[TBL] [Abstract][Full Text] [Related]
10. Impact of deletion of envelope-related genes of recombinant Sendai viruses on immune responses following pulmonary gene transfer of neonatal mice.
Tanaka S; Yonemitsu Y; Yoshida K; Okano S; Kondo H; Inoue M; Hasegawa M; Masumoto K; Suita S; Taguchi T; Sueishi K
Gene Ther; 2007 Jul; 14(13):1017-28. PubMed ID: 17460720
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Benefits and Adverse Effects of Combined Proangiogenic Gene Therapy in Mouse Critical Leg Ischemia.
Lebas B; Galley J; Renaud-Gabardos E; Pujol F; Lenfant F; Garmy-Susini B; Chaufour X; Prats AC
Ann Vasc Surg; 2017 Apr; 40():252-261. PubMed ID: 27903483
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy for therapeutic angiogenesis in peripheral arterial disease - a systematic review and meta-analysis of randomized, controlled trials.
Hammer A; Steiner S
Vasa; 2013 Sep; 42(5):331-9. PubMed ID: 23989068
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of multi-gene cell therapy in patients with peripheral artery disease.
Grossman PM; Mohler ER; Roessler BJ; Wilensky RL; Levine BL; Woo EY; Upchurch GR; Schneiderman J; Koren B; Hutoran M; Gershstein D; Flugelman MY
Vasc Med; 2016 Feb; 21(1):21-32. PubMed ID: 26584888
[TBL] [Abstract][Full Text] [Related]
14. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease.
Morishita R; Aoki M; Hashiya N; Makino H; Yamasaki K; Azuma J; Sawa Y; Matsuda H; Kaneda Y; Ogihara T
Hypertension; 2004 Aug; 44(2):203-9. PubMed ID: 15238569
[TBL] [Abstract][Full Text] [Related]
15. Safety of a non-viral plasmid-encoding dual isoforms of hepatocyte growth factor in critical limb ischemia patients: a phase I study.
Henry TD; Hirsch AT; Goldman J; Wang YL; Lips DL; McMillan WD; Duval S; Biggs TA; Keo HH
Gene Ther; 2011 Aug; 18(8):788-94. PubMed ID: 21430785
[TBL] [Abstract][Full Text] [Related]
16. Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen.
Yonemitsu Y; Ueda Y; Kinoh H; Hasegawa M
Front Biosci; 2008 Jan; 13():1892-8. PubMed ID: 17981677
[TBL] [Abstract][Full Text] [Related]
17. Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicenter, double-blind, placebo-controlled trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease.
Rajagopalan S; Olin JW; Young S; Erikson M; Grossman PM; Mendelsohn FO; Regensteiner JG; Hiatt WR; Annex BH
Hum Gene Ther; 2004 Jun; 15(6):619-24. PubMed ID: 15212720
[TBL] [Abstract][Full Text] [Related]
18. Phase Ib Safety, Two-Dose Study of MultiGeneAngio in Patients with Chronic Critical Limb Ischemia.
Flugelman MY; Halak M; Yoffe B; Schneiderman J; Rubinstein C; Bloom AI; Weinmann E; Goldin I; Ginzburg V; Mayzler O; Hoffman A; Koren B; Gershtein D; Inbar M; Hutoran M; Tsaba A
Mol Ther; 2017 Mar; 25(3):816-825. PubMed ID: 28143739
[TBL] [Abstract][Full Text] [Related]
19. RIG-I helicase-independent pathway in sendai virus-activated dendritic cells is critical for preventing lung metastasis of AT6.3 prostate cancer.
Kato T; Ueda Y; Kinoh H; Yoneyama Y; Matsunaga A; Komaru A; Harada Y; Suzuki H; Komiya A; Shibata S; Hasegawa M; Hayashi H; Ichikawa T; Yonemitsu Y
Neoplasia; 2010 Nov; 12(11):906-14. PubMed ID: 21076616
[TBL] [Abstract][Full Text] [Related]
20. A phase I clinical study of naked DNA expressing two isoforms of hepatocyte growth factor to treat patients with critical limb ischemia.
Gu Y; Zhang J; Guo L; Cui S; Li X; Ding D; Kim JM; Ho SH; Hahn W; Kim S
J Gene Med; 2011 Nov; 13(11):602-10. PubMed ID: 22015632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
